Atorvastatin/ezetimibe - Althera Pharmaceuticals
Latest Information Update: 29 Apr 2021
At a glance
- Originator Althera Pharmaceuticals
- Class Amides; Antihyperlipidaemics; Azetidines; Fatty acids; Fluorobenzenes; Heptanoic acids; Propanols; Pyrroles
- Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Hypercholesterolaemia
Most Recent Events
- 30 Mar 2021 Atorvastatin/ezetimibe - Althera Pharmaceuticals is available for licensing as of 30 Mar 2021. https://altherapharma.com/partnerships/
- 26 Mar 2021 Preregistration for Hypercholesterolaemia in Europe (PO)
- 26 Mar 2021 Preregistration for Hypercholesterolaemia in USA (PO)